News
RNA
12.16
-0.90%
-0.11
Weekly Report: what happened at RNA last week (0803-0807)?
Weekly Report · 2d ago
This Lyell Immunopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday
Benzinga · 6d ago
Zillow downgraded, Global Payments upgraded: Wall Street’s top analyst calls
TipRanks · 6d ago
Atrium Therapeutics Initiated at Buy by HC Wainwright & Co.
Dow Jones · 6d ago
Atrium Therapeutics Price Target Announced at $25.00/Share by HC Wainwright & Co.
Dow Jones · 6d ago
HC Wainwright & Co. Initiates Coverage On Atrium Therapeutics with Buy Rating, Announces Price Target of $25
Benzinga · 6d ago
Atrium Therapeutics initiated with a Buy at H.C. Wainwright
TipRanks · 6d ago
Weekly Report: what happened at RNA last week (0727-0731)?
Weekly Report · 08/03 10:33
Weekly Report: what happened at RNA last week (0720-0724)?
Weekly Report · 07/27 10:38
Weekly Report: what happened at RNA last week (0713-0717)?
Weekly Report · 07/20 10:34
Wells Fargo Remains a Buy on Atrium Therapeutics, Inc. (RNA)
TipRanks · 07/16 09:45
Atrium Therapeutics Gains FDA IND Clearance For ATR 1072 In PRKAG2 Syndrome
NASDAQ · 07/14 13:17
Atrium Therapeutics announces FDA clearance of ATR 1072 IND application
TipRanks · 07/14 10:40
Atrium Therapeutics Says FDA Clears IND Application Allowing It To Move Forward With Corventis Phase 1/2 Clinical Trial To Evaluate ATR 1072 For Treatment Of PRKAG2 Syndrome
Benzinga · 07/14 10:33
Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome
PR Newswire · 07/14 10:30
Weekly Report: what happened at RNA last week (0706-0710)?
Weekly Report · 07/13 10:36
Weekly Report: what happened at RNA last week (0629-0703)?
Weekly Report · 07/06 10:41
Weekly Report: what happened at RNA last week (0622-0626)?
Weekly Report · 06/29 10:34
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PR Newswire · 06/23 20:05
Weekly Report: what happened at RNA last week (0615-0619)?
Weekly Report · 06/22 10:46
More
Webull provides a variety of real-time RNA stock news. You can receive the latest news about Atrium Therapeutics, Inc through multiple platforms. This information may help you make smarter investment decisions.
About RNA
Atrium Therapeutics, Inc. is a biopharmaceutical company engaged in the delivery of ribonucleic acid (RNA) therapeutics for people living with cardiomyopathy. Its technology leverages the targeted RNA delivery platform, which combines the tissue selectivity of monoclonal antibodies (mAbs) and other targeted delivery ligands with oligonucleotides. It is designed to allow selective targeting of the underlying genetic drivers of disease. Its development pipeline consists of programs that target genetically validated drivers of cardiomyopathy, which include Protein Kinase AMP-Activated Non-Catalytic Subunit Gamma 2 (PRKAG2) and Phospholamban (PLN). Its genetic drivers are associated with PRKAG2 syndrome and PLN cardiomyopathy, which is a genetic heart condition associated with life-threatening forms of heart disease. Its programs are supported by preclinical data, in addition to positive clinical data generated in neuromuscular indications using the same RNA delivery platform technology.